Eva Morava, MD,PhD
About Me
Dr. Eva Morava completed her specialty training in both Europe and the United States, specializing in pediatrics, genetics, and metabolic disorders. She brings decades of experience in diagnosing, treating, and managing inborn errors of metabolism (IEM), with a particular focus on congenital disorders of glycosylation (CDG) and mitochondrial disorders.
Dr. Morava has served on newborn screening committees in multiple states and has been a council member of the Society for the Study of Inborn Errors of Metabolism (SSIEM). She is actively involved in the development of novel therapies for genetic disorders, with her current focus on clinical trials in IEM. She serves as the Principal Investigator for the U54 FCDGC consortium, which is dedicated to studying congenital disorders of glycosylation.
CDG encompasses more than 180 distinct genetic disorders, many of which have only 4-10 known patients worldwide. In response to these ultra-rare conditions, Dr. Morava and her team have established a nationwide network of regional centers aimed at developing treatments to address the unmet needs of this patient population. The mission of the FCDGC consortium is to improve clinical outcomes, quality of life, and life expectancy for individuals with CDG through advancing knowledge, developing and validating new diagnostic tools, and creating therapies that restore appropriate glycosylation.
Since 2018, Dr. Morava has served as Editor and Editor-in-Chief of the Journal of Inherited Metabolic Disease. In 2023, she became the Editor-in-Chief of Molecular Genetics and Metabolism, a journal committed to publishing the latest research and clinical findings in IEM. Her research laboratory focuses on translational research in mitochondrial disorders and CDG. With over 350 publications to her name, Dr. Morava collaborates closely with organizations like the United Mitochondrial Disease Foundation (UMDF) and CDG CARE, where she serves on the advisory board. She is also the co-chair for the MSSM site for the National Organization for Rare Disorders (NORD).
Dr. Morava is deeply committed to education, particularly in the realm of patient education. She plays a key role in course development and education at the North American Metabolic Academy, oversees the Medical Genetics Residency and Fellowship Program, and directs the Program for Inherited Metabolic Diseases at the Department of Genetics and Genomic Sciences, Division of Medical Genetics and Genomics at Mount Sinai.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
About Me
Dr. Eva Morava completed her specialty training in both Europe and the United States, specializing in pediatrics, genetics, and metabolic disorders. She brings decades of experience in diagnosing, treating, and managing inborn errors of metabolism (IEM), with a particular focus on congenital disorders of glycosylation (CDG) and mitochondrial disorders.
Dr. Morava has served on newborn screening committees in multiple states and has been a council member of the Society for the Study of Inborn Errors of Metabolism (SSIEM). She is actively involved in the development of novel therapies for genetic disorders, with her current focus on clinical trials in IEM. She serves as the Principal Investigator for the U54 FCDGC consortium, which is dedicated to studying congenital disorders of glycosylation.
CDG encompasses more than 180 distinct genetic disorders, many of which have only 4-10 known patients worldwide. In response to these ultra-rare conditions, Dr. Morava and her team have established a nationwide network of regional centers aimed at developing treatments to address the unmet needs of this patient population. The mission of the FCDGC consortium is to improve clinical outcomes, quality of life, and life expectancy for individuals with CDG through advancing knowledge, developing and validating new diagnostic tools, and creating therapies that restore appropriate glycosylation.
Since 2018, Dr. Morava has served as Editor and Editor-in-Chief of the Journal of Inherited Metabolic Disease. In 2023, she became the Editor-in-Chief of Molecular Genetics and Metabolism, a journal committed to publishing the latest research and clinical findings in IEM. Her research laboratory focuses on translational research in mitochondrial disorders and CDG. With over 350 publications to her name, Dr. Morava collaborates closely with organizations like the United Mitochondrial Disease Foundation (UMDF) and CDG CARE, where she serves on the advisory board. She is also the co-chair for the MSSM site for the National Organization for Rare Disorders (NORD).
Dr. Morava is deeply committed to education, particularly in the realm of patient education. She plays a key role in course development and education at the North American Metabolic Academy, oversees the Medical Genetics Residency and Fellowship Program, and directs the Program for Inherited Metabolic Diseases at the Department of Genetics and Genomic Sciences, Division of Medical Genetics and Genomics at Mount Sinai.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
